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that are known to be difficult to clone and stably maintain in E. 137 coli. As shown in Extended data Figure 1d -h, we followed the same strategy to prepare the 138 genome termini in cloned plasmids to include genetic elements that are later needed for virus 139 rescue (e.g. T7-RNA polymerase promoter, cleavages sites or ribozyme elements) and 140 produced a set of overlapping DNA fragments covering the rest of the genome. This strategy 141 proved to be successful irrespectively of the source of virus or nucleic acid template or the 142 number of DNA fragments that were used for the one-step assembly in yeast. Of note, we 143 were also able to clone hRSV-B, without any prior information on the virus genotype, directly 144 from a clinical sample (nasopharyngeal aspirate) by designing RSV consensus primers to 145 8 amplify 4 overlapping DNA fragments (sequence submitted to GenBank). Collectively, these 146 results demonstrate the synthetic genomics platform provides the technical advance to rapidly 147 generate molecular clones of diverse RNA viruses by using viral isolates, cloned DNA, 148 synthetic DNA, and even clinical samples as starting material. 149 The appearance of a novel CoV in China at the end of 2019 prompted us to go a step further 150 and to test the applicability of our synthetic genomics platform to reconstruct the virus based 151 on its released genome sequence and chemically synthesized DNA fragments. Notably, at the 152 time when the first genome sequences of SARS-CoV-2 were released (Jan 10/11 th , 2020) no 153 virus isolate has been made available and it took until the end of January 2020 when 154 successful isolation of SARS-CoV-2 was reported from patients in Australia 155 (https://www.the-scientist.com/news-opinion/australian-lab-cultures-new-coronavirus-as-156 infections-climb-67031). We fragmented the genome into 12 subgenomic DNA fragments 157 ranging in size between 0.5-3.4 kbp ( Fig. 3a , Extended Data Figure 1i , Extended Data Tables 158 1, 4). In parallel, we also aimed to generate a SARS-CoV-2 expressing GFP that could be 159 valuable to facilitate the establishment of serological diagnostics (e.g. virus neutralization 160 assay) and detection in cell culture. To do this we divided fragment 11 into 3 sub-fragments which was inserted in frame within the ORF7a. We noticed at the 5' end of the reported 163 SARS-CoV-2 sequence that nucleotides 3-5 (5'-AUUAAAGG; Genbank MN996528.1) were 164 different compared to the closely related SARS-CoV (5'-AUAUUAGG; GenBank 165 AY291315) and to the even more closely related bat SARS-related CoVs ZXC21 and ZC45 166 (5'-AUAUUAGG) 18 , and that for all three the 5'-end has been experimentally determined by 167 5 18, 19 . Therefore, we designed three 5'-end versions of fragment 1 containing the 168 reported SARS-CoV-2 sequence (fragment 1.3; 5'-AUUAAAGG), a version modified by 3 169 nucleotides (fragment 1.1; 5'-AUAUUAGG), and a version containing the 124 5'-terminal 170 nucleotides spanning the first four 5'-terminal stem-loop structures of SARS-CoV (fragment 171 9 1.2; Fig. 3b ). Notably, nucleotide differences between SARS-CoV-2 and SARS-CoV within 172 this region are in agreement with the predicted RNA secondary structures ( Fig. 3b ). 173 We ordered the synthetic DNA constructs on January 14 th (Fig. 3d , Extended data Table 4 , 174 Extended Data Document 1), and until February 4 th 12 of 14 constructs were delivered as 175 sequence-confirmed plasmids. However, fragments 5 and 7 turned out to be problematic to 
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We expect that the fast, robust and versatile synthetic genomics platform we describe here 202 will provide new insights into the molecular biology and pathogenesis of a number of 203 emerging RNA viruses and will specifically facilitate the molecular characterization of the 204 novel coronavirus SARS-CoV-2. Although homologous recombination in yeast has already 205 been used for the generation of a number of molecular virus clones in the past 13,14,21 , we 206 present here a thorough evaluation of the feasibility of this approach to rapidly generate full-207 length cDNAs for large RNA viruses that have a known history of instability in E. coli. We 208 show that one main advantage of the TAR cloning system is that the viral genomes can be 209 fragmented to at least 14 overlapping fragments and re-assembled with remarkable efficacy 210 (usually >90% of the clones are correct). This allowed us to complete the cloning and rescue 211 of rSARS-CoV-2 and rSARS-CoV-2-GFP within one week. It should also be noted that we 212 see considerable potential to reduce the time of DNA synthesis. Currently, synthetic DNA 213 fragments are still routinely cloned in E. coli, which turned out to be problematic for SARS-214 CoV-2 fragments 5 and 7. We could however use 4 and 3 shorter dsDNA parts of fragments 5 215 and 7, respectively, that we received, to assemble the full-length fragments 5 and 7 by TAR 216 cloning which is an additional proof of the superior cloning efficiency of our yeast system 217 versus E. coli-based systems. This allowed us to generate a molecular clone of SARS-CoV-2 218 by using exclusively chemically synthesized DNA, and the rescue of this version is currently 219 in progress.
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The appearance of SARS-CoV-2 emphasizes the need for preparedness to rapidly respond to 221 emerging virus threats. While the availability of SARS-CoV-2 isolates is still limited, full 222 11 virus genome sequences were disclosed very early during the outbreak. The rapidity of our 223 synthetic genomics approach to generate SARS-CoV-2 and the applicability to other 224 emerging RNA viruses make this system an attractive alternative to provide infectious virus 225 to health authorities and diagnostic laboratories without the need to have access to clinical 226 samples. Finally, as the SARS-CoV-2 outbreak is ongoing, we expect to see sequence 227 variations and possibly phenotypic changes of evolving SARS-CoV-2 in the human host.
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With the synthetic genomics platform it is now possible to introduce such sequence variations 229 into the infectious clone and to functionally characterize SARS-CoV-2 evolution in real-time. 
